Chest Medicine
Why Opening Windows Is a Key to Reopening Schools
18 Mar, 2021 | 09:02h | UTCWhy Opening Windows Is a Key to Reopening Schools – The New York Times (free registration may be required)
Commentary on Twitter
https://twitter.com/trishgreenhalgh/status/1372180956094865409
COVID-19 vaccines vs. variants—determining how much immunity is enough
18 Mar, 2021 | 08:58h | UTCCOVID-19 Vaccines vs Variants—Determining How Much Immunity Is Enough – JAMA
Population Study: Past Covid-19 confers 80.5% protection against reinfection, which decreases to 47.1% in those aged 65 years and older
18 Mar, 2021 | 09:06h | UTCCommentaries: Risk of SARS-CoV-2 reinfection after natural infection – The Lancet AND COVID-19 Reinfection: More Common Than We Think? – MedPage Today (free registration required)
Commentary on Twitter
NEW—Most people who have had original #COVID19 strain are protected from catching it again for at least 6 months—but those ≥65 years are more prone to reinfection, suggests first large-scale study of its kind. Read https://t.co/250Yv0a9BZ pic.twitter.com/BTjhcMzXwT
— The Lancet (@TheLancet) March 17, 2021
Immunogenicity of a single dose of SARS-CoV-2 mRNA vaccine in solid organ transplant recipients
17 Mar, 2021 | 02:55h | UTC
RCT: Oxford/AstraZeneca vaccine does not protect against mild-to-moderate Covid-19 due to the B.1.351 variant
17 Mar, 2021 | 03:01h | UTCCommentaries: AstraZeneca vaccine doesn’t prevent B1351 COVID in early trial – CIDRAP AND Oxford/AstraZeneca Fails to Prevent Mild to Moderate Covid-19 From B.1.351 (“South Africa”) Variant – Brief19
FDA: Why you should not use Ivermectin to treat or prevent COVID-19
17 Mar, 2021 | 02:51h | UTCWhy You Should Not Use Ivermectin to Treat or Prevent COVID-19 – U.S. Food & Drug Administration
Commentary: FDA Rejects Ivermectin, Despite Growing Interest In Some Corners Of The Internet – Brief19
Related: RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19
COVID antibody treatments show promise for preventing severe disease
17 Mar, 2021 | 02:46h | UTCCOVID antibody treatments show promise for preventing severe disease – Nature
Update on the safety of COVID-19 Vaccine AstraZeneca
16 Mar, 2021 | 02:35h | UTCUpdate on the safety of COVID-19 Vaccine AstraZeneca
Related: Countries should continue AstraZeneca rollout: WHO – MedicalXpress AND Expert reaction to news that Germany has halted vaccinations with the Oxford-AstraZeneca COVID-19 vaccine – Science Media Centre AND AstraZeneca finds no evidence of increased blood clot risk from vaccine – Reuters AND Data suggest no increased risk of blood clots from the AstraZeneca vaccine. Australia shouldn’t pause its rollout – The Conversation
Commentary on Twitter
As of March 8th, Around 17 million people in the EU & UK received the vaccine , there have been 15 events of DVT & 22 events of pulmonary embolism reported among those given the vaccine,This is much lower than would be expected to occur naturally in a general population
Please RT https://t.co/tnn4brxwpp— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) March 14, 2021
B.1.1.7 variant linked to 55% higher mortality compared to other strains of SARS-CoV-2
16 Mar, 2021 | 02:32h | UTCOriginal study: Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7 – Nature
Related: Death rate 64% higher with B117 COVID variant, study finds (study and commentary)
Commentary on Twitter (thread – Click for more)
https://mobile.twitter.com/_nickdavies/status/1371441682089132032
Antibody response after SARS-CoV-2 infection and implications for immunity: A rapid living review
16 Mar, 2021 | 02:30h | UTC
ACP Practice Points: What is the antibody response and role in conferring natural immunity after SARS-CoV-2 infection?
16 Mar, 2021 | 02:29h | UTC
More than half of COVID-19 patients report depressive symptoms months later, study finds
16 Mar, 2021 | 02:11h | UTCOriginal study: Association of Acute Symptoms of COVID-19 and Symptoms of Depression in Adults – JAMA Network Open
Commentary on Twitter
Survey study finds 52% of individuals with prior #COVID19 met criteria for moderate or greater symptoms of depression; more likely in younger, male, and those with more severe #COVID19 @royperlis @HarvardMed @Ognyanova @RutgersU @NorthwesternU @dellavolpe https://t.co/4krNvFb29T
— JAMA Network Open (@JAMANetworkOpen) March 13, 2021
The oxygen cascade during exercise in health and disease
16 Mar, 2021 | 01:28h | UTCThe Oxygen Cascade During Exercise in Health and Disease – Mayo Clinic Proceedings
Perspective | New lung cancer screening guideline comes with many caveats
14 Mar, 2021 | 20:23h | UTCNew lung cancer screening guideline comes with many caveats – Lown Institute
Original Guideline: USPSTF Statement: begin screening for lung cancer at age 50 years instead of 55 years for patients at risk (article and commentaries)
New COVID-19 risk calculator can predict severe disease or death among hospitalized patients with COVID-19
14 Mar, 2021 | 20:54h | UTCSee calculator: Severe COVID-19 Adaptive Risk Predictor (SCARP)
WHO adds Janssen vaccine to list of safe and effective emergency tools against COVID-19
14 Mar, 2021 | 20:57h | UTC
Commentary on Twitter (thread – click for more)
https://twitter.com/hildabast/status/1370537307392987141
[Preprint] RCT: Full-dose/therapeutic anticoagulation provides no benefit in critically ill patients with Covid-19
14 Mar, 2021 | 20:59h | UTCTherapeutic Anticoagulation in Critically Ill Patients with Covid-19-Preliminary Report – medRxiv
Related (results on moderately ill patients): [Not published yet] Full-dose Heparin best for moderate COVID-19 regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials
Covid vaccinations: No reason to stop using AstraZeneca jab, says WHO
14 Mar, 2021 | 20:46h | UTCCovid vaccinations: No reason to stop using AstraZeneca jab, says WHO
See also: Benefits Of AstraZeneca Vaccine Outweigh Risks, Say EMA and WHO Officials – Urging Jabs To Continue While Safety Data Around Blood Clots Is Reviewed – Health Policy Watch AND COVID-19 Vaccine AstraZeneca: PRAC investigating cases of thromboembolic events – vaccine’s benefits currently still outweigh risks – Update – European Medicines Agency AND Canada says AstraZeneca vaccine is safe after Norway and Denmark suspend use – Reuters
Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes
14 Mar, 2021 | 20:43h | UTCEpidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes – Science
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
14 Mar, 2021 | 20:44h | UTCMultiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity – Cell
Commentary: Vaccine-induced antibodies may be less effective against several new SARS-CoV-2 variants
Commentary on Twitter (thread – click for more)
Our paper describing the potential for mRNA vaccines to induce antibodies capable of neutralizing many of the circulating variants is now available online at Cell!https://t.co/c8B87Tg55S pic.twitter.com/eRM8ABJrQY
— Balazs Lab (@BalazsLab) March 12, 2021
Study: Healthcare settings did not increase the risk for Covid-19 infection among health care workers in the US. Exposure outside the workplace was the strongest risk factor for SARSCoV2 seropositivity
14 Mar, 2021 | 20:41h | UTCCommentaries: Healthcare settings do not increase risk for Covid-19 infection spread – University of Maryland School of Medicine AND Did Healthcare Workers Catch Covid In Or Outside The Hospital? – MedicalResearch.com AND Community Covid-19 Risk Higher Than Workplace Risk for Health Care Personnel – Physician’s Weekly
Commentary on Twitter
Cross-sectional study finds #COVID19 exposure outside the workplace was the strongest risk factor for #SARSCoV2 seropositivity. No workplace factors were associated with seropositivity. @EmoryMedicine @UMMC @HopkinsMedicine @CDCgov https://t.co/DbdSxTEb8n
— JAMA Network Open (@JAMANetworkOpen) March 10, 2021
M-A: Early tracheostomy may lower the rates of ventilator-associated pneumonia and ventilator duration in critically ill patients
12 Mar, 2021 | 08:09h | UTCAuthor interview: Early vs Late Tracheotomy for Pneumonia and Ventilator Days
#Tracheostomy placement no more than 7 days after ventilator support may lower the rates of ventilator-associated pneumonia and ventilator duration https://t.co/gVPXoMEorN @Penn_ENT @UTHealthSA
— JAMA Otolaryngology – Head & Neck Surgery (@JAMAOto) March 11, 2021
[Press release – not published yet] Novavax reports 96% efficacy against original strain of COVID-19, 86% efficacy against B.1.1.7 variant, and 55% efficacy against B1.351 variant
12 Mar, 2021 | 08:33h | UTCPress release: Novavax Confirms High Levels of Efficacy Against Original and Variant COVID-19 Strains in United Kingdom and South Africa Trials
Commentaries: Novavax Reports Its COVID-19 Vaccine is 96% Efficacious, Based on Phase 3 Trial Results – TIME AND Novavax Says Vaccine Is 96% Effective At Preventing Original Covid-19 Virus – Forbes
Commentary on Twitter
https://twitter.com/m_scribe/status/1370126020121083913
ERS Guideline: Management of hospitalized adults with COVID-19
12 Mar, 2021 | 08:36h | UTC
NCCN Best Practices Guidance: Management of COVID-19 Infection in Patients with Cancer
12 Mar, 2021 | 08:31h | UTC